IM-202: A randomized, open-label, multicenter, phase 1b/2 trial evaluating the safety and efficacy of intratumorally-administered ilixadencel in combination with checkpoint inhibitor (CPI) in advanced cancer subjects who are candidates for CPI therapy (the ILIAD study)

November 12, 2018
Cancer - Esophageal, Cancer - Head and Neck, Cancer - Lung
Principal Investigator: Ding Wang, MD
Advanced cancer, head and neck cancer, head and neck cancer advanced, non-small-cell lung cancer, gastric cancer, gastroesophgeal junction adenocarcinoma